gdc
Multiple Myeloma

Creating an Open Dialogue with Providers

Yelak Biru points out the importance of patients being able to set up an ongoing dialogue with their providers outside of the formal appointment settings.
Video Library – February 4, 2016
Yelak Biru
Patient, North Texas Myeloma Support Group Leader; Member, International Myeloma Foundation; Advisory Committee Chair, Global Myeloma Action Network

Usually, when you get a home-administered drug, oral especially, they tell you what I called earlier the operational aspect of it. How do you get it? How do you order it and things like that.

Then all of the unexpected side effects of the drug, you don't always have a good way of being able to communicate with your provider outside of a formal appointment. You need to be able to find ways in partnership with your provider to actually have a more open and a more frequent dialogue without necessarily always having an appointment and without always having to travel to the provider's office.

Because one of the benefits of orally administered drugs is, as much as I like my doctors, I don't want to see them as often as I see them. As a result, having a way of me being able to report the side effects, either through a patient portal or a mobile application or some other means, I think is really important in my opinion.

With today's technology like wearable technologies or a mobile devices and data that's available all the time, and data that the patients generate, the providers can have almost close to real-time information about the patient's condition in order to be able to interact with them and leverage technology in the 21st century.

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma
In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
Multiple Myeloma
CAR T-Cell Therapies Produce Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
By Chase Doyle
Cell-based therapy is becoming an attractive option for the treatment of patients with relapsed (coming back) or refractory (does not respond to therapy) multiple myeloma who have received many therapies before.
Multiple Myeloma
Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma
By Chase Doyle
In patients with newly diagnosed multiple myeloma, the use of the 3-drug combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone for first-line therapy does not improve outcomes compared with the 3-drug combination of Velcade (bortezomib), lenalidomide, and dexamethasone, which is the current standard of care for this patient population.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Blenrep for Patients with Relapsed or Refractory Multiple Myeloma
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Last modified: October 5, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country